Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Quarterly Earnings Preview
- Expected Earnings Report: Anticipated EPS loss of $2.84 and projected revenue of $45 million.
- Financial Health Indicators: Mixed financial metrics with a price-to-sales ratio of 2.56 and a debt-to-equity ratio of 0.54.
- Profitability Challenges: Negative P/E ratio of -0.49 and earnings yield of -2.06% highlight ongoing losses.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a prominent player in the field of cell programming and biosecurity. The company is preparing to release its quarterly earnings on Tuesday, November 12, 2024. Wall Street anticipates a challenging quarter, with an expected earnings per share (EPS) loss of $2.84 and projected revenue of $45 million.
To provide insights into its performance, DNA will host a presentation and Q&A session on the same day at 5:30 p.m. ET. This event will be accessible through Ginkgo's investor relations website, with a replay available for those unable to attend live. This session aims to offer clarity on the company's financial health and strategic direction.
DNA's financial metrics reveal a mixed picture. The price-to-sales ratio of 2.56 suggests that the market values its sales moderately. However, the enterprise value to sales ratio of 1.04 indicates a lower valuation when accounting for debt and cash. This could imply that investors see potential in the company's sales despite its current challenges.
The company's debt-to-equity ratio of 0.54 reflects a moderate level of debt compared to its equity, suggesting a balanced approach to financing. Additionally, a current ratio of 4.71 highlights strong liquidity, indicating DNA's ability to cover short-term liabilities effectively. These figures suggest a stable financial position in terms of liquidity and debt management.
Despite these strengths, DNA faces profitability challenges. A negative P/E ratio of -0.49 and an earnings yield of -2.06% indicate ongoing losses. Furthermore, the enterprise value to operating cash flow ratio of -0.65 points to difficulties in generating positive cash flow from operations. These metrics underscore the hurdles DNA must overcome to achieve profitability.
| Symbol | Price | %chg |
|---|---|---|
| 207940.KS | 1044000 | 3.35 |
| 068270.KS | 172300 | 1.97 |
| 196170.KQ | 398000 | 1.38 |
| 091990.KQ | 75900 | 0 |
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Quarterly Earnings Preview
- Expected Earnings Report: Anticipated EPS loss of $2.84 and projected revenue of $45 million.
- Financial Health Indicators: Mixed financial metrics with a price-to-sales ratio of 2.56 and a debt-to-equity ratio of 0.54.
- Profitability Challenges: Negative P/E ratio of -0.49 and earnings yield of -2.06% highlight ongoing losses.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a prominent player in the field of cell programming and biosecurity. The company is preparing to release its quarterly earnings on Tuesday, November 12, 2024. Wall Street anticipates a challenging quarter, with an expected earnings per share (EPS) loss of $2.84 and projected revenue of $45 million.
To provide insights into its performance, DNA will host a presentation and Q&A session on the same day at 5:30 p.m. ET. This event will be accessible through Ginkgo's investor relations website, with a replay available for those unable to attend live. This session aims to offer clarity on the company's financial health and strategic direction.
DNA's financial metrics reveal a mixed picture. The price-to-sales ratio of 2.56 suggests that the market values its sales moderately. However, the enterprise value to sales ratio of 1.04 indicates a lower valuation when accounting for debt and cash. This could imply that investors see potential in the company's sales despite its current challenges.
The company's debt-to-equity ratio of 0.54 reflects a moderate level of debt compared to its equity, suggesting a balanced approach to financing. Additionally, a current ratio of 4.71 highlights strong liquidity, indicating DNA's ability to cover short-term liabilities effectively. These figures suggest a stable financial position in terms of liquidity and debt management.
Despite these strengths, DNA faces profitability challenges. A negative P/E ratio of -0.49 and an earnings yield of -2.06% indicate ongoing losses. Furthermore, the enterprise value to operating cash flow ratio of -0.65 points to difficulties in generating positive cash flow from operations. These metrics underscore the hurdles DNA must overcome to achieve profitability.
